Harvard Apparatus Regenerative Technology secured a $300,000 bridge loan bearing a fixed 8% annual interest rate, due on the earlier of a $5 million capital raise or April 13 2027. The infusion adds liquidity to a company whose shares sit at $1.00 and have fallen 45.7% year‑to‑date, offering investors a runway to support a potential turnaround.

Key Highlights

  • Bridge Note carries fixed 8% annual interest, providing a cost‑effective financing option.
  • Repayment triggers on a $5 million capital raise or by April 13 2027, whichever occurs first.
  • Shares have slid 45.7% YTD, reflecting market skepticism despite the new funding.

Harvard Apparatus Regenerative Technology (OTC: HRGN) obtained a $300,000 bridge loan on April 13, 2026, with a fixed 8% annual interest rate. The infusion comes as the company seeks to sustain its regenerative‑technology pipeline while investors watch a market‑cap of $18 million.

$300,000 Bridge Note Secured

The bridge note was executed between the company and its chairman‑CEO, Junli He, who agreed to loan the full $300,000 amount. The instrument is senior, unsecured, and includes a fixed interest rate of 8% per annum, calculated on the outstanding principal. Interest accrues daily and compounds annually, with the total due on the earlier of the specified capital‑raise threshold or the April 13, 2027 maturity date.

The note also grants the lender a discretionary conversion right into equity, allowing He to become a shareholder under predetermined terms. By securing the loan from internal leadership, the company avoids dilutive external financing, though the conversion feature may still affect future share count.

Loan Terms and Conversion Rights

The 8% fixed rate sits above typical short‑term market rates, reflecting the elevated risk profile of a biotech firm with a market cap of $18 million. Covenants within the note require the company to maintain compliance with all existing agreements and to avoid any event of default, such as missed payments or breach of material terms. Should a default occur, the lender can accelerate repayment or enforce security interests.

The optional conversion at the lender’s discretion provides a pathway to equity if the company’s valuation improves, potentially aligning interests between management and investors. However, conversion could modestly dilute existing shareholders, an outcome that market participants must weigh against the liquidity benefit.

Market Context and Investor Implications

The bridge note’s $300,000 infusion represents a modest but material addition to a company with a $18 million market capitalization, effectively extending its operational runway by several months pending a larger financing event. This additional liquidity may enable the firm to advance clinical studies, retain key talent, or meet regulatory milestones that could reverse the steep share‑price decline. Investors should monitor how the company allocates the borrowed funds, as prudent use could rebuild confidence, while misallocation may deepen the discount.

Upcoming Maturity and Funding Milestone

The next decisive event is the bridge note’s maturity on April 13, 2027, unless the company secures gross proceeds of at least $5 million before that date. A successful capital raise would extinguish the loan early, preserving cash and avoiding interest expense, while also signaling market validation of the firm’s pipeline. Conversely, failure to meet the $5 million threshold could force repayment at maturity, potentially straining liquidity and pressuring the stock further.

The outcome of this financing milestone will likely be a focal point for analysts ahead of the company’s upcoming quarterly report, where earnings and cash‑flow statements will reveal whether the bridge loan has stabilized operations.

Analysis based on the Form 8-K filed 3 August 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.